Business Context and Reporting Period
This Form 8-K was filed by Nuvilex, Inc. (noted as Pharmacyte Biotech, Inc. in metadata) on October 1, 2009. The report discloses an unregistered sale of equity securities involving a private placement to an accredited investor.
Key Financial Metrics
The filing details a specific capital raise event rather than periodic financial performance. Key transaction metrics include:
- Cash Investment: $250,000
- Shares Issued: 5,555,555 restricted shares of Common Stock
- Price Per Share: $0.045
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in outstanding common stock by 5,555,555 shares and the receipt of $250,000 in cash. The investor, Mr. Robert S. Trump, acquired the shares based on his personal experience with the company's retail products, Cinnergen and Cinnechol.
Guidance, Outlook, and Risks
Management commentary indicates the investment supports the company's growth strategy and business plans. The transaction was executed under Section 4(2) of the Securities Act of 1933, exempting it from registration requirements as it did not involve a public offering or general solicitation. No specific forward-looking guidance, risk factors, or contingencies beyond the standard exemption language are provided in this report.
Investor Verification Checklist
- Verify the current total share count and dilution impact of the 5,555,555 new shares.
- Confirm the company's current cash position post-transaction to assess runway.
- Review the status of the restricted shares and any applicable lock-up periods under Rule 144.
- Validate the company's operational progress regarding the Cinnergen and Cinnechol product lines mentioned as the catalyst for the investment.